How effective is Adalimumab for ulcerative colitis?

The use of adalimumab for ulcerative colitis is generally considered to be effective in reducing complications of affected patients related to the disease. Adalimumab is usually used only if other treatment proves ineffective or in patients who have a medium to severe ulcerative colitis. Despite positive findings, the use of adalimumab for ulcerative colitis has some potentially severe side effects, including hepatitis B virus reactivation in previously infected patients, opportunistic infections, tuberculosis, allergic reactions and increased chances of lymphoma.

ulcerative colitis is a type of inflammatory intestinal disorder that causes ulceration in a colon lining. The extent and severity of the disease may vary from patients. Ulcerative colitis is believed to be caused by immune cells that normally protect the body from infection. The disease may develop throughout their lives, but is more common in people of reproductive age.Mu and women are equally prone, but in people JewishA slightly higher incidence can be seen.

artificial monoclonal antibody, adalimumab inhibits pro -inflammatory protein called factor of necrosis (TNF). It is subcutaneous through one -off, in advance filled syringes. The typical dose of adalimumab for ulcerative colitis and other inflammatory bowel disorders is 40 milligrams every other week. Other TNF inhibitor medicines include etanercept and infliximab.

Adalimumab for ulcerative colitis works by blocking the effects of factor of tumor necrosis and reducing the hyperactivity of the immune system, which generally characterizes disorders of inflammatory intestines. Adalimumab has several drug interaction options that include other TNF and methotrexate inhibitors. Patients who are in adalimumab treatment should not use live vaccines. The drug certainly suppresses the immune system, so the risks of adalimumab include increased susceptibility to infections and slightlyhigher incidence of cancer such as lymphoma.

ulcerative colitis has different forms and different degrees of severity. Adalimumab is generally used for refractory forms of the disease that includes several areas of the large intestine. Many scientific studies have been conducted in the effects of Adalimumab. They usually focus on drug efficacy as possible independent therapy or combined therapy in patients who are affected by ulcerative colitis. Studies show that adalimumab treatment is more effective in reducing complications of ulcerative colitis than lack of treatment.